尼塔佐克桑化物通过改善肠道屏障和抑制炎症来预防实验性性结肠炎
Hu-Tai-Long Zhu1, Jing Luo1, Yi Peng1
1Department of Pharmacology, China Pharmaceutical University, Nanjing, People's Republic of China.
尼塔佐胺通过改善肠道屏障功能和减少炎症,有效治疗性结肠炎. 这项研究揭示了它的机制,包括激活AMPK和抑制JAK2/STAT3信号通路.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎是一种影响结肠的慢性炎症状况.
- 尼塔佐胺是一种抗原类药物,具有已知的抗炎性质.
- 以前的研究表明,尼塔佐胺及其代谢物蒂佐胺激活AMPK并抑制炎症.
研究的目的:
- 研究尼塔佐胺对小鼠中硫酸 (DSS) 诱导的大肠炎的治疗作用.
- 阐明尼塔佐胺在结肠炎中的作用的潜在分子机制.
主要方法:
- 在DSS诱导大肠炎后,小鼠被口服尼塔佐胺.
- 评估疾病活动指数 (DAI),体重,结肠长度,肠道屏障功能和炎症性细胞因子表达 (IL-6,IL-17).
- 在体外和体内研究了尼塔佐胺和蒂佐胺对AMPK,JAK2 / STAT3信号传递,CDX2表达,紧结蛋白 (ZO-1,occludin) 和巨细胞极化 (M2) 的影响.
主要成果:
- 尼塔佐胺治疗显著改善了结肠炎症状,包括减少DAI,改善体重和缩短结肠长度.
- 尼塔佐胺改善了肠道屏障功能,并降低了结肠组织中的IL-6和IL-17水平.
- 在机械上,尼塔佐化/提佐化激活AMPK,抑制JAK2/STAT3信号传递,增加CDX2和紧结蛋白表达,并促进M2巨细胞两极分化.
结论:
- 尼塔佐胺在小鼠中显示出对DSS诱导的性结肠炎的保护作用.
- 治疗效益归因于增强肠道屏障完整性和抑制炎症.
- 关键的机制包括AMPK激活和JAK2/STAT3通路的抑制.
更多相关视频
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
